Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Schmid H, Lederer SR. Novel iron-containing phosphate binders for treatment of hyperphosphatemia. Expert Opin Pharmacother. 2015;16(14):2179–91.
2. Brunelli SM, Sibbel SP, Van Wyck D, et al. Net budgetary impact of ferric citrate as a first-line phosphate binder for the treatment of hyperphosphatemia: A Markov microsimulation model. Drugs R D. 2017;17:159–66. doi:
10.1007/s40268-016-0163-7
.
3. Rodby R, Umanath K, Dwyer J, et al. Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data. Drugs R D. 2015;15(3):271–9.
4. Mutell R, Rubin J, Bond T, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013;6:79–87.
5. Chiu Y, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96.